AVXL - Anavex Life Sciences Corp Stock Price, Fair Value and News

$8.63+0.16 (+1.89%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AVXL Price Action

Last 7 days

2.0%

Last 30 days

1.8%

Last 90 days

53.0%

Trailing 12 Months

-1.4%

AVXL RSI Chart

AVXL Valuation

Market Cap

731.8M

Price/Earnings (Trailing)

-17.62

Price/Sales (Trailing)

27.56

EV/EBITDA

-17.47

Price/Free Cashflow

-24.39

AVXL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AVXL Fundamentals

AVXL Revenue

Revenue (TTM)

21.0M

Rev. Growth (Yr)

-6.9%

Rev. Growth (Qtr)

11.44%

AVXL Earnings

Earnings (TTM)

-41.5M

Earnings Growth (Yr)

-8.28%

Earnings Growth (Qtr)

-15.82%

AVXL Profitability

EBT Margin

-197.62%

Return on Equity

-32%

Return on Assets

-29.34%

Free Cashflow Yield

-4.1%

AVXL Investor Care

Shares Dilution (1Y)

3.47%

Diluted EPS (TTM)

-0.5

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	21.0M	0
2021	31.6M	55.3M	79.1M	50.0M
2020	3.0M	3.7M	7.5M	7.8M
2019	2.8M	1.7M	2.5M	3.0M
2018	0	3.7M	1.6M	2.0M
2017	1.1M	1.5M	2.0M	0
2016	781.4K	758.1K	571.1K	0
2015	0	0	0	776.9K
2013	131.3K	129.2K	176.3K	182.6K
2012	165.4K	150.6K	142.9K	139.2K
2011	91.1K	124.7K	158.2K	180.0K
2010	0	0	24.1K	57.6K

Get all data in R, Python etc through our Historical Stock Data APIs

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

CEO	Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
WEBSITE	anavex.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	38

Anavex Life Sciences Corp Frequently Asked Questions

What is the ticker symbol for Anavex Life Sciences Corp? What does AVXL stand for in stocks?

AVXL is the stock ticker symbol of Anavex Life Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anavex Life Sciences Corp (AVXL)?

As of Fri Dec 20 2024, market cap of Anavex Life Sciences Corp is 731.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVXL stock?

You can check AVXL's fair value in chart for subscribers.

Is Anavex Life Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether AVXL is over valued or under valued. Whether Anavex Life Sciences Corp is cheap or expensive depends on the assumptions which impact Anavex Life Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVXL.

What is Anavex Life Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, AVXL's PE ratio (Price to Earnings) is -17.62 and Price to Sales (PS) ratio is 27.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVXL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anavex Life Sciences Corp's stock?

In the past 10 years, Anavex Life Sciences Corp has provided 0.277 (multiply by 100 for percentage) rate of return.